Inflammation Research

, Volume 60, Issue 3, pp 281–287

The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease

  • Naja Dam Mygind
  • Marina J. Harutyunyan
  • Anders Bruun Mathiasen
  • Rasmus S. Ripa
  • Jens Jacob Thune
  • Jens Peter Gøtze
  • Julia S. Johansen
  • Jens Kastrup
  • The CLARICOR Trial Group
Original Research Paper

DOI: 10.1007/s00011-010-0266-5

Cite this article as:
Mygind, N.D., Harutyunyan, M.J., Mathiasen, A.B. et al. Inflamm. Res. (2011) 60: 281. doi:10.1007/s00011-010-0266-5

Abstract

Objective

The inflammatory biomarker YKL-40 is elevated and associated with mortality in patients with stable coronary artery disease (CAD). The aim was to investigate the influence of statin treatment and lipid status on serum YKL-40 and Hs-CRP in patients with stable CAD.

Design

Serum YKL-40, HsCRP, total cholesterol, HDL-c, LDL-c and triglycerides levels were measured in 404 statin treated and in 404 matched non-statin treated patients with stable CAD.

Results

YKL-40 was significantly higher in non-statin treated 110 µg/l (median) compared with 65 µg/l in statin treated (p < 0.001). HsCRP was 3.3 mg/l in non-statin treated compared with 2.1 mg/l in statin treated (p < 0.001).

YKL-40 was not related to cholesterol levels for either statin or non-statin treated patients in the univariate analysis. In statin treated patients, HsCRP was related to a high level of total-cholesterol (p = 0.01) and a low level of HDL-c (p < 0.001).

Conclusions

HsCRP, but not YKL-40, is associated with the cholesterol levels in statin treated patients. This indicates that YKL-40 could be a superior prognostic biomarker in patients with stable CAD, since it is independent of changes in cholesterol levels in both statin and non-statin treated patients.

Keywords

Coronary artery disease Inflammation Biomarkers Statin treatment YKL-40 HsCRP 

Copyright information

© Springer Basel AG 2010

Authors and Affiliations

  • Naja Dam Mygind
    • 1
  • Marina J. Harutyunyan
    • 1
  • Anders Bruun Mathiasen
    • 1
  • Rasmus S. Ripa
    • 2
  • Jens Jacob Thune
    • 1
  • Jens Peter Gøtze
    • 3
  • Julia S. Johansen
    • 4
  • Jens Kastrup
    • 1
  • The CLARICOR Trial Group
  1. 1.Cardiac Catheterization Laboratory 2014, Department of Medicine B, Faculty of Health Sciences, The Heart Centre, RigshospitaletCopenhagen University HospitalCopenhagen ØDenmark
  2. 2.Department of Clinical Physiology and Nuclear MedicineFrederiksberg HospitalFrederiksbergDenmark
  3. 3.Department of Clinical Biochemistry, RigshospitaletCopenhagen University HospitalCopenhagenDenmark
  4. 4.Department of Medicine, Herlev HospitalCopenhagen University HospitalCopenhagenDenmark

Personalised recommendations